NZ630011A - Method for treating gynecological diseases - Google Patents

Method for treating gynecological diseases

Info

Publication number
NZ630011A
NZ630011A NZ630011A NZ63001113A NZ630011A NZ 630011 A NZ630011 A NZ 630011A NZ 630011 A NZ630011 A NZ 630011A NZ 63001113 A NZ63001113 A NZ 63001113A NZ 630011 A NZ630011 A NZ 630011A
Authority
NZ
New Zealand
Prior art keywords
progesterone receptor
gynecological diseases
treating gynecological
pharmaceutical composition
combination
Prior art date
Application number
NZ630011A
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Valérie Boujac
Ernest Loumaye
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of NZ630011A publication Critical patent/NZ630011A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ630011A 2012-03-23 2013-03-22 Method for treating gynecological diseases NZ630011A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
EP12160956.4A EP2641602A1 (en) 2012-03-23 2012-03-23 Method for treating gynecological diseases
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Publications (1)

Publication Number Publication Date
NZ630011A true NZ630011A (en) 2016-12-23

Family

ID=45976689

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630011A NZ630011A (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Country Status (18)

Country Link
US (1) US10441534B2 (enExample)
EP (3) EP2641602A1 (enExample)
JP (2) JP2015514700A (enExample)
KR (1) KR20140138824A (enExample)
CN (1) CN104203246A (enExample)
AU (1) AU2013236960B2 (enExample)
CA (1) CA2864073A1 (enExample)
CO (1) CO7111317A2 (enExample)
EA (1) EA031488B1 (enExample)
GE (1) GEP201706696B (enExample)
HK (1) HK1199827A1 (enExample)
MX (1) MX369520B (enExample)
MY (1) MY172530A (enExample)
NZ (1) NZ630011A (enExample)
SG (1) SG11201404921QA (enExample)
TW (2) TW201400121A (enExample)
WO (1) WO2013140372A1 (enExample)
ZA (1) ZA201407575B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
CN110099915A (zh) 2016-10-07 2019-08-06 欧瑞克制药公司 糖皮质激素受体抑制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
KR101229701B1 (ko) 2004-07-09 2013-02-05 라보라토이레 에이치알에이 파르마 프로게스테론 수용체 조절제를 함유하는 서방형 조성물
US8569274B2 (en) * 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
LT2249757T (lt) * 2008-02-04 2017-09-25 Ferring B.V. Vientisi intravaginaliniai žiedai, apimantys progesteroną, ir jų gamybos bei panaudojimo būdai

Also Published As

Publication number Publication date
KR20140138824A (ko) 2014-12-04
CA2864073A1 (en) 2013-09-26
CN104203246A (zh) 2014-12-10
AU2013236960B2 (en) 2017-11-23
TW201832767A (zh) 2018-09-16
GEP201706696B (en) 2017-07-10
JP2015514700A (ja) 2015-05-21
HK1199827A1 (en) 2015-07-24
MX2014011487A (es) 2015-01-12
MX369520B (es) 2019-11-11
TW201400121A (zh) 2014-01-01
US10441534B2 (en) 2019-10-15
JP2018109025A (ja) 2018-07-12
EP2641602A1 (en) 2013-09-25
CO7111317A2 (es) 2014-11-10
ZA201407575B (en) 2015-12-23
US20150038476A1 (en) 2015-02-05
WO2013140372A1 (en) 2013-09-26
MY172530A (en) 2019-11-29
EP2827873A1 (en) 2015-01-28
EA031488B1 (ru) 2019-01-31
AU2013236960A1 (en) 2014-09-25
SG11201404921QA (en) 2014-10-30
EA201491614A1 (ru) 2015-01-30
EP3363500A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12014502516B1 (en) Formulations and methods for vaginal delivery of antiprogestins
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
JOP20130236B1 (ar) تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha
MX2016008362A (es) Combinaciones farmaceuticas.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX362275B (es) Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MX2014004202A (es) Uso post-agudo y profiláctico de progesterona para mejores resultados asociados con concusión.
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
NZ630011A (en) Method for treating gynecological diseases
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
HK1215391A1 (zh) 使用胎盘细胞外基质治疗口腔病变
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
MX368943B (es) Formulaciones de tripeptido liofilizado estables en almacenamiento.
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
WO2011049954A3 (en) Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 MAR 2020 BY DENNEMEYER + CO.

Effective date: 20170413

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 MAR 2021 BY DENNEMEYER + CO.

Effective date: 20200219

LAPS Patent lapsed